SCHEMBL20135504

SCHEMBL20135504

CC(C)C1(c2ccc(C(=O)N3CCC(n4cc5cc(Cl)ccc5n4)CC3)cc2)NC(=O)NC1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.38
PIK3CA P42336 2/20 0.38
PRKAA2 P54646 2/20 0.38
HSD11B1 P28845 1/20 0.35
CNR1 P21554 2/20 0.35
ACACB O00763 2/20 0.35
ACACA Q13085 2/20 0.35
ADAMTS5 Q9UNA0 4/20 0.35
ADAM17 P78536 3/20 0.34
CNR2 P34972 1/20 0.34
MGLL Q99685 2/20 0.34
MAPT P10636 1/20 0.34
CHRM1 P11229 2/20 0.34
TLR8 Q9NR97 1/20 0.33
CCNK O75909 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
CDK7 P50613 1/20 0.33
CCNH P51946 1/20 0.33
MNAT1 P51948 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135501 1.00 KDM5A (0.38) KDM5APIK3CAPRKAA2HSD11B1CNR1
SCHEMBL20809267 0.91 KDM5A (0.38) KDM5APIK3CAPRKAA2ACACBACACA
SCHEMBL20135610 0.90 KDM5A (0.38) KDM5APIK3CAPRKAA2ACACBACACA
SCHEMBL20135608 0.90 KDM5A (0.38) KDM5APIK3CAPRKAA2ACACBACACA
SCHEMBL20135142 0.88 KDM5A (0.47) KDM5AHSD11B1ACACBACACAADAMTS5
SCHEMBL20135143 0.88 KDM5A (0.47) KDM5AHSD11B1ACACBACACAADAMTS5
SCHEMBL20135378 0.83 TLR8 (0.41) HSD11B1ACACBACACAADAMTS5ADAM17
SCHEMBL20135377 0.83 TLR8 (0.41) HSD11B1ACACBACACAADAMTS5ADAM17
SCHEMBL20135079 0.80 LMNA (0.46) ADAMTS5ADAM17MAPT
SCHEMBL29688315 0.80 LMNA (0.46) ADAMTS5ADAM17MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 KDM5A 1526/4885PIK3CA 3049/4885PRKAA2 3857/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 KDM5A 1488/4885PIK3CA 3145/4885PRKAA2 3996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.